ClinicalTrials.gg
RecruitingNCT07514754GALENOS 2Updated Apr 7, 2026

Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients

An interventional study of Galenic Immunonutrition Formula in Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer and Lung Cancer, sponsored by Fondazione del Piemonte per l'Oncologia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Fondazione del Piemonte per l'Oncologia · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2025, registered Mar 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy — 44 open to participants now, 62 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Italy.

Planned enrollment
89th of 109
52 · median 194
Started
2025
with 10 others
No phase
8 of 129
6 open now
Primary completion
2027-07
later than 30 of 61 live
Registered
126th of 129
by date
Lead sponsor
3 of 129
Fondazione del Piemonte per l'Oncologia

Among the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, this one is the 89th largest by planned enrollment of the 109 interventional ones that give a count, is one of 11 that started in 2025, is one of 8 with no phase, reaches primary completion later than 30 of the 61 other live ones, and was the 126th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

44 of the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, or all of them as a file.
02

Study summary

GALENOS 2 is a single-arm, single-center, phase II interventional study designed to evaluate the effects of a galenic immunonutrition dietary supplement in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer undergoing standard antineoplastic treatment. The study aims to assess whether the formula may reduce treatment-related toxicity and improve treatment compliance, using patients from the GALENOS 1 observational study as the control group for comparison

Read the detailed description

This prospective interventional study will enroll adult patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer who are candidates for standard chemoradiotherapy, chemotherapy, radiotherapy, or immunotherapy according to clinical practice. All enrolled participants will receive a galenic immunonutrition formula twice daily starting on the first day of antineoplastic treatment and continuing for up to 45 days, in addition to standard nutritional counseling and routine oncologic care. The study will prospectively assess treatment-related toxicity, nutritional status, body composition, muscle function, cytokine profiles, quality of life, physical activity, treatment adherence/tolerance, and compliance with the galenic formula. Outcomes in GALENOS 2 will be compared with matched or pooled control patients from the GALENOS 1 observational study

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • Locally Advanced Rectal Cancer
  • Lung Cancer

Keywords

  • Immunonutrition
  • Head and Neck Squamous Cell Carcinoma
  • Locally Advanced Rectal Cancer
  • Lung Cancer
  • Treatment Toxicity
  • Supportive Care
  • Body Composition
  • Nutritional Status
  • Cytokines
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written to study procedures
  • Male or female, age greater than 18 years
  • Histological or cytological documentation of head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer candidate for immunotherapy, chemotherapy, and/or radiotherapy according to standard clinical practice
  • Performance Status score less than 2
  • Adequate kidney, liver, and bone marrow function
  • Ability to understand, sign informed consent, and comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Incomplete recovery from surgery before starting antineoplastic treatment
  • Other progressing or malignancy requiring active treatment within the last 3 years, except localized basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ
  • Active infection requiring systemic antibiotic therapy
  • Serious or unstable medical conditions, psychiatric disorders, or substance abuse interfering with study compliance
  • Receipt of any within 30 days before study treatment
  • Active cardiac pacing/pacing implants/neurostimulators/hearing system not compatible with bioimpedance analysis
  • Edema and/or ascites not compatible with body weight evaluation and bioimpedance analysis
  • Enteral or parenteral nutritional support at baseline
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Experimental: Galenic Immunonutrition Formula

    Participants with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer undergoing standard antineoplastic treatment will receive the galenic immunonutrition formula twice daily from treatment start for a maximum of 45 days, alongside routine nutritional counseling and standard clinical management

    Dietary Supplement: Galenic Immunonutrition Formula

Interventions

  • Dietary supplementGalenic Immunonutrition Formula

    The investigational galenic immunonutrition formula is a jelly-based oral supplement formulated with arginine, brewer's yeast, omega-3 powder, olive oil, soy lecithin, glycerol, animal gelatine, purified water, citrate components, and flavoring, with sugar-containing or sweetener-containing versions and peach or lemon flavor options. Participants will receive two servings per day starting on the first day of antineoplastic treatment and continuing for up to 45 days. The product will be prepared and supplied free of charge by the Hospital Pharmacy of FPO-IRCCS Candiolo

06

What researchers measure

Primary outcomes

  1. Participants with at least 1 Grade 3 or higher treatment-related adverse event

    Number of participants with at least 1 treatment-related adverse event of Grade 3 or higher, assessed according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)

    Time frame: From the first day of antineoplastic treatment to end of trial, assessed up to 63 days

Secondary outcomes

  1. Body weight

    Body weight measured in kilograms (kg)

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  2. Body mass index

    Body mass index calculated as body weight in kilograms divided by height in meters squared (kg/m²)

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  3. Daily oral energy intake

    Average daily oral energy intake assessed from food record and expressed in kilocalories per day (kcal/day).

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  4. Nutritional Risk Screening 2002 score

    Nutritional risk assessed using the Nutritional Risk Screening 2002 (NRS-2002). Total score ranges from 0 to 7, with higher scores indicating greater nutritional risk and worse nutritional status

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  5. Prognostic Nutritional Index

    Prognostic Nutritional Index (PNI). Higher values indicate better nutritional and immunologic status

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  6. Participants requiring additional nutritional support

    Number of participants requiring additional oral, enteral, or parenteral nutritional support during the study period

    Time frame: From the first day of treatment to end of trial, assessed up to 63 days

  7. Skeletal muscle mass

    Skeletal muscle mass measured by bioimpedance analysis and expressed in kilograms (kg)

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  8. Fat-free mass

    Fat-free mass measured by bioimpedance analysis and expressed in kilograms (kg).

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  9. Body cell mass

    Body cell mass measured by bioimpedance analysis and expressed in kilograms (kg).

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  10. Fat mass

    Fat mass measured by bioimpedance analysis and expressed in kilograms (kg).

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  11. Total body water

    Total body water measured by bioimpedance analysis and expressed in liters (L)

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  12. Skeletal muscle index

    Skeletal muscle index measured by bioimpedance analysis and expressed in kg/m²

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  13. Phase angle

    Phase angle measured by bioimpedance analysis and expressed in degrees. Higher values generally indicate better cellular integrity

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  14. Handgrip strength

    Maximum handgrip strength measured using a handgrip dynamometer and expressed in kilograms (kg).

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  15. Handgrip endurance

    Handgrip endurance measured using a handgrip dynamometer.

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  16. ECOG Performance Status score

    Performance status assessed using the Eastern Cooperative Oncology Group (ECOG) Performance Status scale. Scores range from 0 to 5, with higher scores indicating worse functional impairment

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  17. Toxicity-free survival

    Time from the first day of antineoplastic treatment to the first documented treatment-related adverse event, assessed according to CTCAE v5.0, expressed in days

    Time frame: From the first day of treatment to first toxicity or end of trial, assessed up to 63 days

  18. Relative chemotherapy dose delivered

    Total chemotherapy dose administered expressed as the percentage of the planned chemotherapy dose

    Time frame: From treatment start to end of treatment, assessed up to 63 days

  19. Relative radiotherapy dose delivered

    Total radiotherapy dose administered expressed as the percentage of the planned radiotherapy dose.

    Time frame: From treatment start to end of treatment, assessed up to 63 days

  20. Relative immunotherapy dose delivered

    Total immunotherapy dose administered expressed as the percentage of the planned immunotherapy dose.

    Time frame: From treatment start to end of treatment, assessed up to 63 days

  21. Relative variation in treatment duration

    Variation in actual treatment duration compared with planned treatment duration, expressed as a percentage

    Time frame: From treatment start to end of treatment, assessed up to 63 days

  22. Participants completing the planned treatment schedule

    Number of participants who complete the planned treatment schedule.

    Time frame: From treatment start to end of treatment, assessed up to 63 days

  23. Participants requiring unplanned hospitalization

    Number of participants requiring at least 1 unplanned hospitalization during the study period.

    Time frame: From treatment start to end of trial, assessed up to 63 days

  24. EORTC QLQ-C30 Global Health Status / Quality of Life score

    Self-perceived quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 version 3.0 (EORTC QLQ-C30 v3.0), Global Health Status / Quality of Life scale. Scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: At baseline (T0), during treatment, and at end of trial (T3), assessed up to 63 days

  25. International Physical Activity Questionnaire score

    Physical activity assessed using the International Physical Activity Questionnaire (IPAQ).

    Time frame: From baseline (T0) to end of trial (T3), assessed up to 63 days

  26. Formula compliance

    Compliance with the galenic immunonutrition formula, expressed as the percentage of prescribed daily servings recorded as consumed in the daily intake diary.

    Time frame: From the first day of treatment to Day 45, assessed up to 45 days

  27. Change in circulating CCL2 concentration

    Plasma CCL2 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  28. Change in circulating CCL4 concentration

    Plasma CCL4 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  29. Change in circulating CCL22 concentration

    Plasma CCL22 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  30. Change in circulating CXCL10 concentration

    Plasma CXCL10 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  31. Change in circulating IFN-γ concentration

    Plasma IFN-γ concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  32. Change in circulating IL-2 concentration

    Plasma IL-2 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  33. Change in circulating IL-4 concentration

    Plasma IL-4 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  34. Change in circulating IL-5 concentration

    Plasma IL-5 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  35. Change in circulating IL-6 concentration

    Plasma IL-6 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  36. Change in circulating IL-8 concentration

    Plasma IL-8 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  37. Change in circulating IL-10 concentration

    Plasma IL-10 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  38. Change in circulating IL-12 concentration

    Plasma IL-12 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  39. Change in circulating IL-13 concentration

    Plasma IL-13 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  40. Change in circulating IL-15 concentration

    Plasma IL-15 concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  41. Change in circulating TGF-β concentration

    Plasma TGF-β concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  42. Change in circulating TNF-α concentration

    Plasma TNF-α concentration measured using the Simple Plex system and expressed in picograms per milliliter (pg/mL).

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

  43. Change in C-reactive protein concentration

    C-reactive protein concentration measured in peripheral blood

    Time frame: From baseline (T0) to end of treatment blood sampling, assessed up to 42 days for HNSCC and lung cohorts and up to 31 days for LARC cohort

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2027, 21 months after the start.

Of 116 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 21 months is below that.

Counting every sponsor, half of 127 studies reached it within 59 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartActual
Oct 3, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07514754
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Oct 3, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Valentina Casalone, MD
Contact
valentina.casalone@ircc.it
0119933844 ext. +39

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion